Dermatology News

A broader array of therapies is allowing clinicians to target specific disease domains in psoriatic arthritis, but the treat-to-target “sweet spot” remains unclear, noted a presenter at the 2021 Congress of Clinical Rheumatology-East.

Dermatologists should be prepared to discuss COVID-19 vaccines with their patients who have immune-mediated inflammatory diseases and how biologic treatments may be affected, according to a review.

Juvenile dermatomyositis challenges rheumatologists to accurately assess not only the skin but also pulmonary and cardiac function in making a diagnosis, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.

Women with acne reported concerns about health and appearance, as well as disruptions to their personal and professional lives, according to a study.

The use of biological disease-modifying antirheumatic drugs in patients with psoriasis reduces the risk for psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Dupixent reduced both itch and hives in patients with moderate to severe chronic spontaneous urticaria in a pivotal phase 3 trial, Regeneron and Sanofi announced in a press release.

Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.

Guselkumab 100 mg administered every 4 or 8 weeks produced “meaningful and sustained” improvements in fatigue through 1 year in patients with psoriatic arthritis, according to data published in Arthritis & Research & Therapy.

Both ustekinumab and TNF inhibitors demonstrate significant improvement in psoriatic arthritis disease activity, with similar positive results in minimal and low disease activity, and remission, after 6 months, according to data.

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.